31 OCTOBER - 1 NOVEMBER 2017 | RITZ CARLTON, WASHINGTON DC

Phacilitate

BIG DATA IN PRECISION MEDICINE

PROVIDING AN EXECUTIVE PLATFORM TO FACILITATE THE SHARING OF GENOMIC AND PHENOTYPE DATA TO DRIVE CLINICAL PROGRESS

JOIN THE MOST EXCLUSIVE PRECISION MEDICINE SUMMIT IN THE HEART OF WASHINGTON DC

87% DIRECTOR LEVEL & ABOVE

175+ ATTENDEES

135+ ORGANIZATIONS

40+ EXPERT SPEAKERS

CONFIRMED PRECISION MEDICINE INNOVATORS INCLUDE:

Dr Cecilia Schott,
VP Precision Medicine, Global Product & Portfolio,
AstraZeneca

Mike Restuccia,
SVP CIO,
University of Pennsylvania Health System

Dr Teresa Zayas Caban,
Chief Scientist, Acting Chief of Staff, Office of the National Coordinator for Health Information Technology,
US Department of Health and Human Services

Dr Balazs Flink,
Head of Clinical Trial Analysis,
Bristol Myers Squibb

Dr Jean-Claude Zenklusen,
Director, Cancer Genome Atlas, National Cancer Institute,
National Institute of Health

Dr Andrew Kernytsky,
Head of Computational Biology,
CRISPR Therapeutics

"Excellent speakers representing multiple stakeholders in creating and utilizing big data in precision medicine."

Dr William Dalton, CEO, M2Gen

REGISTER NOW AT **WWW.BIGDATALEADERSFORUM.COM**

AGENDA

DAY 1 // 31st October 2017

The path from Big Data to precision medicine

08.30 CHAIR INTRODUCTION – THE PATH FROM DATA ANALYTICS TO PRECISION MEDICINE
- What are the challenges in combining comprehensive data, collected over time, from genetics, environment and lifestyle, to advance disease understanding and interception, aid drug discovery and ensure delivery of appropriate therapies?

08.35 [PANEL] THE CHALLENGES OF ADAPTING DRUG DEVELOPMENT AND HEALTHCARE TO THE AGE OF PERSONALIZED THERAPIES
- How are we setting research objectives within biopharma for 'precision medicine' and how will new insight translate into advancement for clinical investigations/experimental therapeutics?
- If our vision of precision medicine is to deliver diagnostic tests and to identify responsive patients, alongside new targeted therapies, what pressure will this put on development resources, including the unprecedentedly large volumes of data early in preclinical and clinical testing?
- How can the industry plan to recoup development costs with precision drugs targeting only a subset of a particular patient population? Where is the profitability?

Panellists:
Dr Rick Dewey, *Senior Director, Head of Translational Genetics,* **Regeneron**
Dr Cecilla Schott, *VP, Precision Medicine, Global Product & Portfolio Strategy,* **Astrazeneca**
Dr Kelly Zou, *Senior Director & Analytic Science Lead, Real World Data & Analytics,* **Pfizer**
Dr Ravinder Dhawan, *Vice President & Head of Oncology, Center for Observational & Real-World Evidence (CORE),* **Merck**

09.10 [RESERVED] ESTABLISHING THE CAPABILITIES TO VALIDATE AND SECURELY MANAGE LARGE, COMPLEX DATA SETS INVOLVED IN MASSIVE GENOME SEQUENCING PROJECTS

09.25 IDENTIFYING THE FUTURE NEEDS FOR BIG DATA IN MEDICINES REGULATION
Dr Sean Khozin, *Senior Medical Officer, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research,* **FDA (Invited)**

09.40 TRANSFORMING THERAPEUTIC DISCOVERY AND DEVELOPMENT USING AN INTEGRATED OMICS STRATEGY
Dr Karen Akinsanya, *Associate Vice President, Translational Research, Insights & Analytics & Partnering,* **Merck**

09.55 [PANEL] FOSTERING A COLLABORATIVE APPROACH TO EVALUATING –OMICS AND PHENOTYPE DATA
- Encouraging collaboration among industry players and other stakeholders: What is the strategy? What can our resources achieve and how do we need to partner?
- How can partnerships in a diverse range of projects and sharing data across a broad research community, increase our understanding for the mechanisms of disease and potentially accelerate the development of clinically useful markers, targets and therapeutics?
- How can we help to accelerate a broad adoption of clinical data standards and fully realize the vision of semantic interoperability, in order to give us the ability to exchange data rapidly with meaning and actionable insights?

Dr Marc S. Williams, *Director, Genomic Medicine Institute,* **Geisinger Health System**
Jonathan Chainey, *Global Head, Data Standards, PD Biometrics,* **Roche**
David R. Bobbitt, MSc, MBA, *President and CEO,* **CDISC**
Dr Jane Wilkinson, *Senior Director, Genomics Platform Projects & Alliances,* **Broad Institute**
Dr Victoria Gamerman, *Head of Health Informatics & Analytics,* **Boehringer Ingelheim**

10.25 [ROUNDTABLE DISCUSSIONS] ESTABLISHING MULTI-STAKEHOLDER DRUG DEVELOPMENT
- The one-company in-house approach of the past has transitioned to a network-driven model that must create closer collaboration between the industry and other parties
- How can we shifting our strategy from an application-centric focus to a data-centric focus; where investigators strive to aggregate data from all sources into a centralized repository, giving clinicians access to this knowledge pool with virtually any analytics tool or user interface

Table 1: Dr Jim Ford, *Director of Clinical Cancer Genomics,* **Stanford Cancer Institute**
Table 2: Dr James O'Leary, *Chief Innovation Officer,* **Genetic Alliance**
Table 3: Collaborative efforts and big data approaches to reduce the burden of common genetic disorders
Chair: Prof Iftikhar Kullo, *Cardiovascular Disease, College of Medicine,* **Mayo Clinic**
Table 4: Christian Schubert, *Director, Business Development & External Innovation,* **Biogen**
Table 5: Hosted by Signet Accel
Table 6: Hosted by PPD
Table 7: Prof John Quackenbush, *Director, Center for Cancer Computational Biology,* **Dana-Farber Cancer Institute;** *CEO,* **GenoSpace**

11.25 CHAIR INTRODUCTION

11.00 **Morning coffee served in the exhibition area**

How are digital technologies supporting precision medicine?

11.30 [PANEL] THE USE OF PUBLIC AND PRIVATE DATABASES TO SUPPORT THE PRACTICE OF GENOMIC MEDICINE
- Is it really acceleration by collaboration? Can innovative partnerships hold great potential for pharma R&D? What is the goal - to look at a subgroup of patients (eg. 10,000) or at each individual?
- The logistical challenges of delivering a large research study – how is it possible to enrol all these patients?
- The scope and role of registries; determining the clinical impact of molecular profiling on disease types

Dr Daniel Auclair, *SVP Research,* **Multiple Myeloma Research Foundation**
Dr Brad Perkins, *Chief Medical Officer,* **Human Longevity**
Dr Amy Abernethy, *Chief Medical Officer,* **FlatIron Health**
Dr Grant Wood, *Clinical Genetics Institute,* **Intermountain Healthcare**

11.55 DATA ANALYSIS IN GENE EDITING
Insight from CRISPR Therapeutics
- Landscape of CRISPR guide sites and their off-targets as well as designing hybrid capture libraries to enrich the genome for off-target edit detection

Dr Andrew Kernytsky, *Head of Computational Biology,* **CRISPR Therapeutics**

12.15 PREDICTIVE MODELING OF HEALTH RISKS AND HEALTH OUTCOMES USING INTEGRATIVE ANALYSES OF CLINICAL, BIOMEDICAL, ENVIRONMENTAL, BEHAVIORAL, AND SOCIO-DEMOGRAPHIC DATAE
Dr Vasant G Honavar, *Professor and Edward Frymoyer Chair of Information Sciences and Technology, and Professor of Computer Science and of Bioinformatics and Genomics, Director, Artificial Intelligence Research Laboratory, Director, Center for Big Data Analytics and Discovery Informatics, Associate Director, Institute for Cyberscience,* **Pennsylvania State University**

12.30 ARTIFICIAL INTELLIGENCE TO FURTHER OUR UNDERSTANDING OF DENGUE DISEASE AND VACCINATION MECHANISMS
Dr Dany DeGrave, *Senior Director Innovation Programs & External Networks,* **Sanofi**

12.45 [RESERVED] WHAT COULD ARTIFICIAL INTELLIGENCE MEAN FOR PHARMA?

13.00 [PANEL] ARTIFICIAL INTELLIGENCE: ACHIEVING PRECISION MEDICINE AT SCALE
- Methods to integrate clinical, molecular, and real world data at large scales to build tremendous cloud-based holistic models for simulation experiments and investigation into disease
- Managing and deriving value from quantitative patient data to understand patient sub-populations, identify biomarkers of disease onset, progression, or patient stratification, assess clinical risk, and uncover mechanistic understanding of disease
- By applying unsupervised deep learning to massive data we expect to identify new biomarkers and precise phenotypes that can serve as the foundation for building personalized diagnostic and treatment pathways

Panellists: speakers of the session plus:
Dr Andrew Swick, *SVP Product Development & Scientific Affairs,* **Life Extension**

13.30 **Buffet Lunch served in the exhibition area**

"A fine meeting with a number of fantastic talks by leaders in industry, academia, and NIH. Speakers were available outside of their presentations for in-depth questions and networking.
Dr Marek Grabowski, Research Scientist, University of Virginia

AGENDA

DAY 1 // 31st October 2017

Organizing medical and genomic knowledge for precision medicine

14.30 CHAIR INTRODUCTION

14.35 LARGE, HETEROGENEOUS, MULTI-SOURCE DATASETS SUPPORT PRECISION MEDICINE
Dr Anthony Kerlavage, *Acting Director, Center for Biomedical Informatics and IT,* National Cancer Institute

14.50 INTEGRATION OF OMICS SCIENCES TO ADVANCE BIOLOGY AND MEDICINE
Dr Andrew Johnson, *Head, Biomedical Informatics, NHLBI Population Sciences Branch, The Framingham Heart Study,* NHLBI

15.05 PRESENTATION RESERVED

15.20 [PANEL] ORGANIZING MEDICAL AND GENOMIC KNOWLEDGE FOR PRECISION MEDICINE
- Integrating large, complex, heterogeneous, multi-source data-sets. What are the latest protocols, and examples from research, on end-to-end data characterization, manipulation, processing, cleaning, analysis and validation?
- Data diversity and quality: What is the right data for precision medicine?

Panellists- speakers of the session plus
Leo Barella, *Chief Enterprise Architect,* AstraZeneca

Transforming datasets into actionable information

14.30 CHAIR INTRODUCTION

14.35 TRANSFORMING THERAPEUTIC DISCOVERY AND DEVELOPMENT USING AN INTEGRATED GENOMICS STRATEGY
Dr Rick Dewey, *Senior Director, Head of Translational Genetics,* Regeneron

14.50 HIGH DEFINITION MEDICINE: A VISION FOR THE UTILITY OF PERSONAL HEALTH DATA
Dr Ali Torkamani, *Director of Genome Informatics & Drug Discovery,* The Scripps Translational Science Institute

15.05 [RESERVED] IDENTIFYING DISEASE BIOMARKERS FROM MULTI-OMIC DATA AND CLINICAL OBSERVATIONS.

15.20 [PANEL] TRANSFORMING DATASETS INTO ACTIONABLE INFORMATION
- Seeking new models to connect expanding sets of disparate, non-identified patient-level data streams to better develop and commercialize next-generation medicines
- The need for practical, evidence-based approaches: improving study design by better linking indications and target endpoints; better patient stratification using better inclusion/exclusion criteria and biomarker-based segmentation approaches; using outcomes analysis to determine optimal care paths; evaluating medical value and real-world evidence in decision-making

Panellists:
Dr Cathy Marshall, *Director, Clinical Data Sciences,* Pfizer
Dr Michael Boedigheimer, *Director, Computational Biology, Medical Sciences,* Amgen
Dr William Dalton, *CEO,* M2Gen

15.45 **Afternoon refreshment**

How is precision medicine initiatives changing drug development?

16.10 CHAIR INTRODUCTION

16.15 USING A PRECISION MEDICINE STRATEGY TO OVERHAUL THE ENTIRE BUSINESS MODEL
- How clinical and real-world evidence can show the efficacy of a given treatment and demonstrate it as a cost-effective and long-term treatment option
- Using a precision medicine strategy how can we overhaul the entire business model across the lifecycle and identify trends and opportunities, even before approaching payers and regulators

Dr Hui Cao, *Executive Director, CoE for RWE,* Novartis

16.30 [PHARMA ROUNDTABLES] SETTING RESEARCH OBJECTIVES WITHIN BIOPHARMA FOR 'PRECISION MEDICINE'
- Using a precision medicine strategy, how can we overhaul the entire business model across the lifecycle and identify trends and opportunities, even before approaching payers and regulators
- Advancing a 'Smart' Data first strategy: If our vision of precision medicine is to deliver diagnostic tests, to identify responsive patients, alongside new targeted therapies, what pressure will this put on development resources, including the unprecedentedly large volumes of data early in preclinical and clinical testing?

Table 1: Utilizing data to better identify new drug candidates and/or treatment indications
Table 2: Identifying disease biomarkers from multi-omic data and clinical observations
Table 3: Text mining and language processing for precision medicine

17.00 [PANEL] TRANSLATING GENOMIC INFORMATION INTO CLINICAL MEDICINE
Dr Jean C. ZenKlusen, *Director, The Cancer Genome Atlas, National Cancer Institute,* National Institutes of Health
Dr Sandy Farmer, *Executive Director, Genome Sciences & Technologies,* Pfizer
Dr Nicholas Marko, *Director of Neurosurgical Oncology,* Geisinger Health

17.30 CLOSE OF DAY 1 CONFERENCE SESSIONS – DRINKS RECEPTION IN THE EXHIBITION AREA

How is precision medicine initiatives changing the delivery of healthcare?

16.10 CHAIR INTRODUCTION

16.15 MEDICAL EDUCATION, BIOMEDICAL RESEARCH AND EXCELLENCE IN PATIENT CARE
Patrick Farrell, *Senior Director, Data Analytics,* Penn Medicine

16.30 [PANEL] WHAT TECHNOLOGY CENTERS ARE DOING TO EMBRACE PRECISION MEDICINE
- Setting objectives in precision medicine – how have initiatives changed with the recent development of large-scale biologic databases, new methods to characterize patients and computational tools for analysing large sets of data
- Beyond hype cycle: What experiments are being done in health systems which are affecting clinical care? What are the near-term focuses (cancers?) and longer-term aims in generating knowledge applicable to the whole range of health and disease?

Joseph Dudas, *Divisional Chair, Enterprise Analytics,* Mayo Clinic
Jeff Waldron, *Executive Directors,* PM Connective
Dr Paul Nagy, *Deputy Director, Johns Hopkins Medicine Technology Innovation Cente,* John Hopkins University School of Medicine
Mike Restuccia, *SVP CIO,* Penn Medicine
Dr Teresa Zayas Caban, *hief Scientist, Acting Chief of Staff, Office of the National Coordinator for Health Information Technology,* US Department of Health and Human Servicese

17.00 [HEALTHCARE ROUNDTABLE] REALIZING THE POTENTIAL OF PRECISION MEDICINE IN HEALTHCARE
- Creating opportunity through new data architecture
- Increasing value and engagement with healthcare analytics
- Overcoming the significant challenges for the broad implementation of precision medicine in healthcare: insufficient evidence generation, data sharing and infrastructure challenges, slow uptake of genomic information into clinical care and research, the economics, and achieving greater patient and clinician engagement and trust

17.30 CLOSE OF DAY 1 CONFERENCE SESSIONS – DRINKS RECEPTION IN THE EXHIBITION AREA

AGENDA

DAY 2 // 1st November 2017

Precision medicine clinical trials

09.00 CHAIR INTRODUCTION

09.05 INTEGRATING CLINICAL TRIAL ANALYTICS SOLUTIONS UNDER ONE CENTRALIZED ORGANIZATION TO DRIVE ENTERPRISE LEVEL DECISION-MAKING THROUGH DATA
- Developing end to end integrated, predictive analytics that set research objectives, help drive R&D strategy and execution with clear ties to long term financial impacts

Dr Balazs Flink, *Head of Clinical Trial Analytics,* Bristol Myers Squibb

09.25 INTEGRATION OF PRE-CLINICAL AND CLINICAL STUDIES TO PUSH RESEARCH FORWARD
- Dealing with the variety of biomedical data and real-world evidence by managing scale and complexity
- Advancing a portfolio of targets through an R&D pipeline using evidence beyond genetic associations and genomic correlations to disease states

Dr Ray Liu, *Sr Director & Head, Advanced Analytics & Statistical Consultation,* Takeda

09.45 ANALYTICS OF INCREASINGLY LARGE REAL-LIFE DATA SETS
- Leverage analytics to turn big data sets into smart systems
- How can real world, clinical evidence inform drug development?

Dr Oliver Luttringer, *Global Head, Modeling & Stimulation, Real World Evidence,* Novartis

10.00 [RESERVED] CONVERTING THE PROMISE OF PRECISION TRIALS INTO VALUE

10.20 PANEL: REAL-WORLD DATA: A NEW OPPORTUNITY TO STRENGTHEN THE PROCESS
Panellists:
Dr Shuvayu Sen, *Executive Director, Outcomes Research & Access,* Merck
Dr Elise Berliner, *Director, Technology Assessment Program, Center for Outcomes & Evidence,* AHRQ

10.45 [TECHNOLOGY SHOWCASE] HOW ARE DIGITAL TECHNOLOGIES IMPACTING HOW WE RUN CLINICAL TRIALS?
HOSTED BY PPD

11.00 **Refreshment break**

Big Data and the promise of precision medicine in cancer

11.30 CHAIR INTRODUCTION

11.35 STANDARDIZED DATA MODEL FOR ONCOLOGY ANALYTICS
Ari Caroline, *Chief Analytics Officer,* Memorial Sloan Kettering Cancer Center

11.50 CROSS-PROGRAM EXPLORATION OF CLINICAL DATA ACROSS THE IMMUNO-ONCOLOGY PORTFOLIO USING DATA LAKES AND VISUALIZATIONS
Philip Ross, *Director of Clinical Translational Data Science,* Bristol Myers Squibb

12.05 [RESERVED]GENOMIC TECHNOLOGIES AND PHENOTYPE DATA TO STRATIFY PATIENT POPULATIONS IN CLINICAL TRIALS

12.20 A PLATFORM FOR PERSONALIZED THERAPY IN MYELOMA
Dr Kenneth Shain, *Scientific Director, Moffitt Myelonma Working Group,* Moffitt Cancer Center

12.35 [PANEL] PREDICT DRUG RESPONSES IN CANCER RESEARCH
Panellists: Speakers of the session

Precision medicine for managing chronic diseases

11.30 CHAIR INTRODUCTION

11.35 HOW PERSONALIZED DATA CAN MAXIMIZE THE EFFECT OF CHRONIC DISEASE TREATMENT
- Correlating genomic insights with environmental, behavioural and medical factors to have a more holistic view of disease

Dr Iris Grossman, *VP, Head of Personalized & Predictive Medicine,* Teva Pharmaceuticals

[CASE STUDIES] PRECISION MEDICINE STRATEGIES IN CHRONIC AIRWAY DISEASES, DIABETES AND CARDIOVASCULAR DISEASE

11.50 CASE STUDY 1
Dr Chengming Gu, *Vice President, Medical Affairs,* Pfizer China

12.10 CASE STUDY 2 RESERVED

12.30 [PANEL] PAVING THE WAY FOR SYSTEMS BIOLOGY AND PRECISION MEDICINE IN MULTIPLE DISEASE AREAS
- How do we get from real world datasets to cell biology?
- Precision insights have the ability to identify distinct patient subgroups, non-genomic mechanisms of disease initiation and

Panellists- speakers of the session plus
Dr Hui Cao, *Executive Director, CoE for RWE,* Novartis

13.10 **Lunch**

Applying precision medicine in neuroscience

14.10 CHAIR INTRODUCTION

14.15 IMMUNO-DEMENTIA: HUMAN GENETICS-GUIDED DRUG DISCOVERY FOR ALZHEIMER'S DISEASE
Dr. Akihiko Koyama, *Head, Integrated Biology Engine,* Andover innovative Medicine Institute

14.30 PRESENTATION RESERVED

14.45 TOWARDS PRECISION MEDICINE IN PSYCHIATRY: BRIDGING THE GAP FROM BIG DATA TO BIG INSIGHTS
Dr Gayle Wittenberg, Head, *Translational Research & Precision Medicine, Pharma R&D IT, Director, Integrative Solutions & Informatics, Neuroscience,* Janssen Research & Development

15.00 [PANEL]: ACCELERATE TRANSLATIONAL AND CLINICAL RESEARCH IN NEUROLOGICAL DISORDERS THROUGH ASSESSING DATA OF NOVEL THERAPIES
- Bringing efficiency strategies and infrastructure to clinical research
- Establishing and managing disease-specific research consortia
- Custom design of clinical research protocols

Panellists, speakers of the session plus:
Dr Alex Sherman, *Director, Strategic Development & Systems, Neurological Clinical Research Institute,* Massachusetts General Hospital

15.25 DATA-DRIVEN INTEROPERABILITY
- Accelerating the impact of research information exchange
- Maximizing existing research data storage and empowering discovery teams
- Mining disparate data as it is, where it is

Dr Philip Payne, *Chief Scientific Officer,* Signet Accel

15.45 **Refreshment break**

16.05 [RESERVED] USING BIG DATA TO UNDERSTAND RARE DISEASES

16.25 INTEGRATED GENOMIC ADVANCES AND ITS IMPACT ON CLINICAL TRIAL DESIGN AND DELIVERY
- Supporting GSK drug assets by using genetic biomarkers to help predict efficacy and better understand adverse events

Dr Charles Cox, *Head of Pharmacogenetics,* GSK

16.45 MOVING TOWARDS GENOMICS DRIVEN PRECISION MEDICINE IN ASIA

17.00 CLOSE OF CONFERENCE

SPEAKERS ALREADY CONFIRMED INCLUDE:

Dr Cecilia Schott
VP Precision Medicine, Global Product & Portfolio
AstraZeneca

Dr Jean-Claude Zenklusen
Director, Cancer Genome Atlas
NCI

Dr Brad Perkins
Chief Medical Officer
Human Longevity

Dr Anthony Kerlavage
Acting Director, Center for Biomedical Informatics and IT
National Cancer Institute

Dr Ray Liu
Senior Director & Head, Advanced Analytics & Statistical Innovation
Takeda Pharmaceuticals

Dr Grant Wood
Clinical Genetics Institute
Intermountain Healthcare

Dr Daniel Auclair
SVP Research Research
MMRF

Dr Paul Nagy
Deputy Director, John Hopkins Medicine Technology
John Hopkins University School of Medicine

Dr James Ford
Director of Clinical Cancer Genomics
Stanford Cancer Institute

Dr Rick Dewey
Senior Director, Head of Translational Genetics
Regeneron

Dr Andrew Johnson
Head, Biomedical Informatics, Population Science Branch
NHLBI

Dr Marc S. Williams
Director, Genomic Medicine Institute
Geisinger Health System

David Bobbitt
President and CEO
CDISC

Cathy Marshall
Director, Clinical Data Sciences
Pfizer

Dr James O'Leary
Chief Innovation Officer
Genetic Alliance

Dr Jane Wilkinson
Senior Director, Genomics Platform Projects & Alliances
Broad Institute

Dr Elise Berliner
Director, Technology Assessment Program, Center for Evidence and Practice Improvement
AHRQ

Dr Kenneth Shain
Scientific Director, Moffitt Myelonma Working Group
Moffitt Cancer Center

Jonathan Chainey
Global Head, Data Standards, PD Biometrics
Roche

Dr Shuvayu Sen
Executive Director, Outcomes Research & Access
Merck

Dr Joseph Dudas
Division Chair, Enterprise Analytics
Mayo Clinic

Dr Alex Sherman
Director, Strategic Development & Systems, Neurological Clinical Research Institute
Massachusetts General Hospital

Dr Iris Grossman
VP, Head of Personalized & Predictive Medicine
Teva Pharmaceuticals

Dr Ali Torkamani
Director of Genome Informatics & Drug Discovery
The Scripps Translational Science Institute

Dr Sandy Farmer
Executive Director, Enterprise Scientific Technology Operations
Pfizer

Dr Hui Cao
Executive Director, CoE for RWE
Novartis

Dr Balazs Flink
Head of Clinical Trial Analysis
Bristol-Myers Squibb

Mike Restuccia
SVP CIO
University of Pennsylvania Health System

Leo Barella
Chief Enterprise Architect
AstraZeneca

Dr Rick Dewey
Senior Director, Head of Translational Genetics,
Regeneron

Dr Philip Ross
Director of Clinical Translational Data Science
Bristol Myers Squibb

Dr Ari Caroline
Chief Analytics Officer
Memorial Sloan Kettering Cancer Center

Dr Kelly Zou
Senior Director & Analytical Science Lead
Pfizer

Jeff Waldron
Executive Director
PM Connective

Dr Andrew Swick
SVP Product Development & Scientific Affairs
Life Extension

Dr Charles Cox
Head of Pharmacogenetics
GSK

Dr Victoria Gamerman
Head of Health Informatics & Analytics
Boehringer Ingelheim

Patrick Farrell
Senior Director, Data Analytics,
Penn Medicine

Dr William Dalton
CEO,
M2Gen

Dr Karen Akinsanya
Associate VP Translational Research, Insights & Partnering
Merck

Dr Ravinder Dhawan
Vice President & Head of Oncology, Center for Observational and Real-World Evidence (CORE)
Merck

Dr Michael Boedigheimer
Director, Computational Biology, Medical Sciences
Amgen

Dr Dany DeGrave
Senior Director Innovation Programs & External Networks
Sanofi

Dr Chengming Gu
Vice President, Medical Affairs
Pfizer

Dr Gayle Wittenberg
Head Translational Research & Precision Medicine
Janssen Research and Development, LLC

Dr Iftikhar Kullo
Principal Investigator, Cardiovascular Disease, College of Medicine
Mayo Clinic

Dr Philip Payne
Chief Scientific Officer
Signet Accel

Dr Nicholas Marko
Director of Neurosurgical Oncology
Geisinger Health

Dr Olivier Luttringer
Global Head, Modeling and Simulation, Real World Evidence
Novartis

Dr Amy Abernethy
Chief Medical Officer
FlatIron Health

Dr Akihiko Koyam
Head of Integrated Biology Engine
Eisai

Dr Teresa Zayas Caban
Chief Scientist, Acting Chief of Staff, Office of the National Coordinator for Health Information Technology
US Department of Health and Human Services

Dr Andrew Kernytsky
Head of Computational Biology
CRISPR Therapeutics

Dr. Akihiko Koyama
Head, Integrated Biology Engine
Andover innovative Medicine Institute

Dr Vasant G Honavar
Professor, Computer Science, Bioinformatics and Genomics, and Neuroscience Graduate Programs, Director, Artificial Intelligence Research Laboratory, Director, Center for Big Data Analytics and Discovery Informatics, Associate Director, Institute for Cyberscience
College of Information Sciences and Technology

Christian Schubert
Director, Business Development & External Innovation
Biogen

Dr Sean Khozin
Senior Medical Officer, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research
FDA (Invited)

WANT TO JOIN THIS STELLAR PANEL?
There are still speaking opportunities available - contact Peter Harkness now on peter.harkness@phacilitate.co.uk or on +44(0)20 7384 8027

More speakers are being confirmed all the time, to see the latest list visit www.bigdataleadersforum.com now!

"Great and enthusiastic mix of people responsible for planning and doing, creating value, solving problems, serving patients."

Mr Jeff Gallagher, CEO, Virginia Bio

Explore a showcase of the latest practical applications from leading data pioneers, and meet the technology experts who can deliver the rapid and crucial business transformation you need

Facilitate partnerships, data-sharing and collaboration with a uniquely holistic and executive audience taking part in discussion-based presentations and roundtable sessions

Identify exactly what datasets and analysis is needed to drive precision medicine forward with a program addressing all types of data

Set research objectives and establish projects at a strategic level with the budget holders and key decision-makers in the largest precision medicine programs

"Great event, right sized to be able to have direct, constructive interaction with national leaders from government, academia, and industry."

Mr Morgan Crafts, Deputy Director, Tech, Life Science, Northrop Grumman

Previous sponsors include:

BIOCRATES, ASCO CANCER LINQ, cloudera, GNS HEALTHCARE, MDCPartners, Medial EarlySign, median, MOLECULAR HEALTH, NORTHROP GRUMMAN, OLINK PROTEOMICS, paradigm4, Perthera, PPD, saama, SevenBridges, Signet Accel

BOOK YOUR CONFERENCE PASS NOW TO SAVE $$$s!

EARLY BIRD

Until Friday 15 September 2017

Delegate Type	Rates
Pharma/Biotech/CRO	$1,795
Academic/Govt/Not-for-Profit	$895
Technology/Service Provider	$2,995

STANDARD RATES

Delegate Type	Rates
Pharma/Biotech/CRO	$1,995
Academic/Govt/Not-for-Profit	$995
Technology/Service Provider	$2,995

FOR INFORMATION ON:

Small company rates • Group discounts • 1 day attendance

Contact Phacilitate now on team@phacilitate.co.uk or call +44 (0)20 7384 7993

JOIN THE CONVERSATION AT **WWW.BIGDATALEADERSFORUM.COM**